News | October 07, 2023
Emmes acquires VaxTRIALS
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Pfizer is likely to show GSK significant competition
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
KRIVIDA TRIVUS detects the specific virus causing a respiratory infection.
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Subscribe To Our Newsletter & Stay Updated
